NO DRAWINGS

(21) Application No. 41485/69 (22) Filed 20 Aug. 1969

(31) Convention Application No. 164817 (32) Filed 2 Sept. 1968 in

(33) France (FR)


(45) Complete Specification published 22 Sept. 1971

(51) International Classification C 07 d 35/10 41/00 A 61 k 27/00

(52) Index at acceptance

C2C3A12A4A 3A12B2 3A12C5 3A7V2A4 3A7V2E2 3A7V2J1 3A7V2L 3A7V4A4 3A7V4E2 3A7V4J3 3A7V4L





10 valves of glyoxylic acid having useful pharmacological properties, to a process for the preparation of such products and to a therapeutic composition containing said derivatives.

The new products of the invention consist of the reaction products of one mole of a

compound of formula:



or a compound of equimolar quantities of the cis and trans forms of this compound (hereinafter referred to as a "mutual salt", when 30 R'=H;

b) or a compound of formula:

with one mole of a compound of formula:


20 in which formula R and R', which may be the same or different, represent hydrogen or a lower alkyl group of 1—8 carbon atoms and R' is hydrogen or a hydroxy group.

According to the compounds (A) and (B)

25 used, the reaction product is:

a) either a compound of formula:

[Price 25p]



in the case where, in starting compounds (A) and (B), R'=H and R''=OH; c) or a mixture of the compounds defined under a) and b) above.

For example when, in starting compound (A), R" is bydrogen, the reaction product is essentially a compound of formula (C), or a mutual stall when R'=H; when, in the starting compounds, R=H or iso. C_hH_s, R'=H' and R''=OH, the reaction product is essentially a compound of formula (D); in other cases, there is obtained a mixture of the compounds defined under a) and b) above, and particularly in the case where R=CH_s, R'=H and R'=OH there is obtained a mixture

of the mutual salt of the cis and trans forms of compound of formula (C) and of compound

of formula (D).

All compounds or mixtures defined under
a), b) and c) above exhibit, to varying degrees,
an antitussive activity useful in human therapeutics and a very low toxicity.

The invention relates also to a process for the preparation of products derived from gly10 oxylic acid, comprising reacting a compound of formula A with a compound of formula B, wherein R, R' and R' have the above defined meanings, and collecting the resulting

reaction product.

The reaction between compound (A) and glyoxylic acid or its ester of formula (B) is generally carried out at room temperature, the glyoxylic acid or its ester preferably being added in equimolecular amount, in aqueous or alcoholic solution (sometimes slightly acidited when a glyoxylic acid ester is used) to

arylethanolamine (A).

Dissolution is made complete by stirring;
heat is generally evolved, which is limited by
cooling under a stream of water, together with
a slight discoloration of the solution. The reaction product crystallizes spontaneously; it is
then suction filtered and recrystallized from
water or an organic solvent, according to the
organical control of the solution of acids of formula
(C) with the corresponding alcohols R'Olf, in
the presence of analydrous hydrochloric acid.

The following non-limiting examples are given to illustrate the invention.

EXAMPLE 1

1) Mutual salt of cis and trans - 4,6 - dihydroxy - 2 - methyl - 1,2,3,4 - tetrahydro - isoquinoline 1 - carboxylic acids (f) (R=CH:: R'=R''=H).

40

(i) (R=CH; K'=R'-H)

To a conical flack constraints [16.76 g (0.1 mole) of a powdered phenyleptrine base is added an equo-water of 9.2 g (0.1 mole) of glysylic aid monohydrate. The mixture is striced cult completely dissolved; heat is evolved. Crystallization is promoted by scretching the reaction is cooled under a support of the complete of th

Analysis Calculated for C₁₁H₁₃NO₄: C% H% N% 59.19 5.87 6.25

60 Found 59.21 5.78 6.45

2) cis - 4,6 - Dihydroxy - 2 - methyl - 1,2,3,4 - tetrahydro - isoquinoline 1 - car-

boxylic acid (Ia) (Formula C)
a) 0.076 mole of the methyl ester of 4,6 dihydroxy - 2 - methyl - 1,2,3,4 - tetrahydro - isoquinoline 1 - carboxylic acid, prepared as in example 4 hereinunder, is heated with 45 ml of 2N sodium hydroxide under refluxing conditions; the precipitate is suction filtered and is then suspended in a few ml of water; the pH is brought to 5-6 with 6N HCl; the material is again suction filtered; it is then washed twice with 15 ml of cooled water, and then with alcohol and with ether. The product is obtained with a yield of 57%, m.p.=225°C with dec. Concentrating the mother-liquors to dryness and taking up the crystalline residue into 18 ml of boiling water makes it possible to collect 1 g of product, which brings the yield up to 63%.

b) The product may also be obtained by methylation of the N - unsubstituted acid (see Example 2, 55 g (0.06 mole) of product of example 2, 13.8 g (0.3 mole) of formic acid and 18 g (0.18 mole) of 30% formalin are refluxed, using a water-bath, during 8 hours. The mixture is taken up into water and neutralized, which causes crystallization of a material cultrely identical with that described

above under a).

3) Trans = 4,6 - Dihydroxy - 2 - methyl = 1,2,3,4 - tetrahydro - iso - quinoline 1 -

carboxylic acid (Ib) (Formula C Glyoxylic acid monohydrate (0.036 mole) 95 is dissolved in 112 ml of dimethylsulfoxide; phenylephine base (0.036 mole) is added thereto, with stirring; the temperature rises then to about 45°C and complete dissolution is obtained, followed by precipitation. Stirring is contained for a further 4 hours, the precipitate is suction filtered through sintered glass and is then washed with dimethylsulfoxide (20 ml) and then with alcohol and with ether. There are recovered 45 g of compound (I) with a yield of 56%. When 400 ml of absolute ethanol and 200 ml of ether are added to the combined filtrates, a gummy mass which crystallizes is produced. This is suction filtered and then washed with alcohol and with ether; thus is isolated trans isomer (Ib) with a yield of 27.8% (22.3 g), m.p. 224—225°C (dec.). When equal parts of (Ia) and (Ib) are dissolved in boiling water, product (I) crystal-115 lizes on cooling.

Example 2

Mutual salt of cis and trans - 4,6 - dihydroxy - 1,2,3,4 - tetrahydro - isoquinoline 1 - carboxylic acid (II) (R'=R''=H). The procedure of Example 1, 1), is used,

The procedure of Example 1, 1), is used, substituting 0.1 mole of phenylephrine with 0.1 mole of norphenylephrine. Yield: 87.4%; m.p.=238°C.

1,247,306

	Analysis Calculated for	C ₁₀ H ₁₁ NO ₄		
5	Found	C% 57.42	H% 5.30	N% 6.69
	a ound	57.53	5.02	6.68

Example 3

Mutual salt of cis and trans - 4,6 - dihydroxy - 2 - ethyl - 1,2,3,4 - tetrahydro isoquinoline 1 - carboxylic acids (III) (R=C₂H_s); R'=R"=H)

The procedure of Example 1, 1), is used, substituting 0.1 mole of phenylephrine with 0.1 mole of N - ethyl - norphenylephrine and substituting the water with ethanol to dissolve the glyoxylic acid. Yield: 80%; m.p. 212°C.

Analysis
Calculated for C₁₂H₁₅NO₄
0 C% H% . N%
60.75 6.37 5.90
Found

EXAMPLE 4

Methyl 4,6 - dihydroxy - 2 - methyl
1,2,3,4 - tetrahydro - isoquinoline carboxylate (IV) (R=CH₃; R'=CH₃;

60.30

6.61 5.75

R"=H)

a) Direct condensation from methyl gly-

20 Phenylephrine (S g; 0.025 mole) is heated in 10 ml of methanol; methyl glyoxylate (2.15 g; 0.025 mole) is cautionsly added to the hot southon; if required, the pH is actified to a value of 2, with hydrochloric acid; the constant of the content of the conten

b) Bisterification of the corresponding acid40 g of Compound (1) of Example 1 dissolved in methanol (400 ml) containing dryhydrochloric acid (40 g) are refluxed during
2 hours; the solution is concentrated to dryness in zeace, over the water-bath, the resto due is taken up into a mixture of methanol
and benzene; it is then again concentrated to
dryness, and the procedure is repeated a number of times to dry the material completely.

ber of times to dry up into 400 ml of methmethanol containing 40 up into 400 ml of methseparations are repeated three times, final
evaporation to dryness is then carried out final
the residue is finally dissolved in water (60
60 ml) containing ammonia (200 ml) at 20° Be.

Crystallization occurs spontaneously; the crystalline product is suction filtered, washed with water and dried.

lst crop: m.p. 159—160°C. Weight:
 18.59 g
 2nd crop (which separates from the filtrate): m.p. 158—160°C, weight:
 14.91 g.
 Total weight: 33.5 g, i.e., a yield of 75.5%

The products obtained under a) and b) 70 are identical.

Analysis Calculated for C₁₂H₁₃NO₄

Found C% H% N% 60.76 6.33 6.91 75

EXAMPLE 5

Ethyl 4,6 - dihydroxy - 2 - methyl - 1,2,3,4 - tetrahydro - isoquinoline carboxylate (V) (R=CH₃; R'=C₂H₃; R''=H) (Formula C)

a) Direct condensation from ethyl glyoxylate
The procedure of Example 4 a) is used, substituting 0.025 mole of nethyl glyoxylate with
0.025 mole of ethyl glyoxylate. mp.=159—
160°. Recrystallized from water, m.p. 168°.
Yield. 40%.

b Esterification

The procedure of Example 4 b) is used, substituting the methanol ic hydrochloric acid solution with ethanol (400 ml) containing dry hydrochloric acid (40 g). The material is suction filtered, washed with water and dried to give the ethyl ester with a yield of 65%. mp.=170°C.

Analysis Calculated for C₁₃H₁₇NO₄

Found C% H% N% 62.14 6.82 5.57 100 62.35 7.04 5.62

Products a) and b) are identical.

EXAMPLE 6

Propyl 4,6 - dihydroxy - 2 - methyl - 1,2,3,4 - 105 tetrahydro - isoquinoline carboxylate (VI) (R=CH_s; R'=C₃H₇; R"=H) (Formula

a) Direct condensation from propyl glyoxylate.

The procedure of Example 4 a) is used, substituting the methyl glyoxylate with 0.025 mole of propyl glyoxylate. This gives a product melting at 157°S after recrystallization from acetone and, from a 2nd crop, the mix-

20

ture of cis (VIa) and trans (VIb) is obtained (Yield: 20%; m.p. 140°).

 b) Esterification The procedure of Example 4 b) is used, substituting the methanol ic hydrochloric acid solution with propanol (400 ml) containing dry hydrochloric acid (40 g); this gives a product which, in recrystallization from acetone, melts at 157°C. Yield: 97%.

Analysis Calculated for C14H15NO4 H% 7.22 5.28 63.38

Found 63.62 7.22 5.44

EXAMPLE 7 Isopropyl 4,6 - dihydroxy - 2 - methyl -1,2,3,4 - tetrahydro - isoquinoline carboxylate (VII) (R=CH3; R'= iso. C3H7; R"=H) (Formula C)

 a) Condensation from isopropyl glyoxylate
 The procedure of Example 4a) is used, substituting 0.025 mole of methyl glyoxylate with 0.025 mole of isopropyl glyoxylate. Re-25 crystallization is carried out from methanol. There are obtained a 1st crop, m.p. 170°C (Yield: 31%) followed by a 2nd crop, m.p. 165°C (yield: 16%) containing both the cis and trans isomers.

30 b) Esterification The procedure of Example 4 b) is used, substituting the methanol ic hydrochloric acid solution with isopropanol (400 ml) containing

dry hydrochloric acid (40 g). A product melt-ing at 168-170°C is obtained. Yield: 50%

Analysis Calculated for C14H19NO4 H% 5.28 7.22 63.38 40 Found 63.32 7.43 5.30

EXAMPLE 8 Butyl 4,6 - dihydroxy - 2 - methyl - 1,2,3,4 isoquinoline carboxylate tetrahydro -(VIII) (R=CH₃; R'=C₄H₆; R"=H) 45 (Formula C)

 a) Condensation from butyl glyoxylate The procedure of Example 4 a) is used, substituting 0.025 mole of methyl glyoxylate 50 with 0.025 mole of butyl glyoxylate. A first crop (yield: 89%) is obtained which, on re-crystallization from methanol, melts at 143— 145°C, followed by a 2nd crop containing both the cis and trans isomers, with a yield 55 of 12%, m.p. about 128°C.

b) Esterification

The procedure of Example 4 b) is used, substituting the methanol ic hydrochloric acid solution with butanel (400 ml) containing dry hydrochloric acid (40 g). A product melting at 143-145°C is obtained.

Analysis Calculated for CisHaNO 5.01 65 64.49 7.58 Found 64.59 7.57 5.20

EXAMPLE 9 Isobutyl 4,6 - dihydroxy - 2 - methyl -1,2,3,4 - tetrahydro - isoquinoline carboxylate (IX) (R=CH₃; R'=iso.C₄H₂; R"=H) (Formula C)

 a) Condensation from isobutyl glyoxylate The procedure of Example 4 a) is used substituting the methyl glyoxylate with 0.025 mole of isobutyl glyoxylate. A first crop (Yield 40%), m.p. 166-168°C is obtained and then a second crop, m.p. about 150°C (Yield: 10%) which is the mixture of the cis and trans isomers.

b) Esterification The procedure of Example 4 b) is used substituting the methanol ic hydrochloric acid solution with isobutanol (400 ml) containing dry hydrochloric acid (40 g). A product melting at 165°C is obtained. Yield: 82%.

Analysis Calculated for C, H, NO. H% 64 49 7.58 5.01 Found 5.06 64.20 7.78

Example 10 Amyl 4,6 - dihydroxy - 2 - methyl - 1,2,3,4 tetrahydro - isoquinoline carboxylate (X) (R=CH₃; R'=C₃H₁₁; R"=H (Formula

a) Condensation from amyl glyoxylate The procedure of Example 4 a) is used substituting the methyl glyoxylate with 0.025 100 mole of amyl glyoxylate. A product melting at 130°C after recrystallization from aqueous methanol is obtained (Yield: 27%).

b) Esterification The procedure of Example 4 a) is used, 105 substituting the methanol ic hydrochloric acid solution with amyl alcohol (400 ml) containing dry hydrochloric acid (40 g). This gives, with a yield of 26.5%, a product which melts at 130°C on recrystallization from aqueous 110

methanol.

Analysis
Calculated for C₁₈H₂₈NO₄
C%
65.51

195° corresponding to one of the isomers in pure form.

		C%	H%	N%					
_		65.51	7.90	4.28	Analysis				
5	Found				Calculated for C12H13	NO			60
		65.69	8.04	4.88	To Cipris	C%.	TI'n/	MTO/	
						60.75	H% 6.37	N% 5.90	
	E	XAMPLE 11			Found	00.75	0.5/	3.90	
	Isoamyl 4,6 - dil	hydroxy - 2	- më	thvl -		60.69	6.48	- 00	
	tetrah - 4ردرسرا	vdro - isogi	inoline	CST-		00.09	0.40	6.05	65
10	boxylate (XI) (R≕CH _s ; I	?′=iso.	C.H.:					
	R"=H) (Form	ula C)			Evan	PLE 14			
					Propyl 4,6 - dihydrox	r. 17:	1		
	a) Condensation	from isoamy	l glyox	rylate	line carboxylate (X	TV (D	180 - 180 T.F. 107.	dmino-	
	ine procedure o	of Example .	4 al io	moder	R"=H) (Formula	-W (K-	п, к –	CaH ₇ ;	
10	substituting the me	thyl glyoxyla	te with	0.025	The procedure of	Evennia	6 h) :-		-
15	more or isoamvi o	IVOXVIate	Vield •	Ano/ .					70
	m.p. 153—155°C;	the product	may t	be re-	(II). On recrystallizat	ion from	50 0/ 0	pound	
	crystallized from ac	queous metha	nol.		methanol, the produc	t melte	of 165	1660	
	b) Farmicons				(Yields=52%).	- mercs	at 105-	-100	
	b) Esterification								
20	The procedure o	r Example	b) is	used,	Analysis				75
		nanoi ic nydi	rochlorio	c acid	Calculated for C15H1,1	۷O.			
	solution with isoam	yı alconol (4	100 ml)	con-		C%	H%	N%	-
	taining dry hydroch	HOTIC ACID (4	0 g). A	pro-		62.14	6.82	5.57	
	duct which, on recr	ystamzation :	from aq	ueous	Found		0.02	5.57	
25	methanol, melts at is thereby obtained	133-133	(xield	19%)		61.97	6.75	5.58	80
	is andeby obtained	•						2.50	
	Analysis								
	Calculated for C10H	L.NO			EXAM	LB 15			
		C%.	Н%	370/-	Isobutyl 4,6 - dihydr	oxy - 1,	2,3,4 -	tetra-	
		65.51	7.90	N% 4.78	nyaro - isoquinblir	e carbo	vviate	CKAN	
30	Found	05.51	7.50	4./0	(R=H; R'=iso.C.	H,; R″=	H) (Fo:	rmula	
		65.38	7.94	4.82	()				85
		05.50	1.54	4.04	The procedure of I	xample !	9 b) is	used,	
	Exa	MPLE 12			substituting compound	. (I) wii	h com	nound	
	Methyl 4,6 - dihve	droxy - 1.2.	3.4 - 1	tetra.	(II). On recrystalliza	tion from	methy	lethyl	
	nyuro - isoduino	line carbor	viate (CETT	ketone, the product	melts at	1481	49°C	
35	(X=H; K'=CH	.: R"=T\	Ramont	M (1)	(Yield: 14%3				90
	The procedure of	Example 4	h) io	a set sort	Analysis				
	substituting the 40	g of compo	ind (II)	with	Calculated for C14H19N	n			
					Cantenated for Cittigate	C%	TTO/	3701	
40						63.38	H% 7.22	N%	
40	duct melting at 180	°C (with de	composi	ition)	Found	05.56	1.22	5.28	05
	is obtained (Yield:	65%).				63.19	7.23	5.27	95
	Analusia					JJ.17	1.23	1.2/	
	Analysis Calculated for C ₁₁ H ₁₀	NO							
	- His	NU ₄	****		Examp:	LE 16			
45		C%	H%:		Isoamyl 4,5 - dihydro	XV - 1.2	3.4 - 1	tetro	
	Found	59.18	5.87		nvaro - isodilimiline	corbov	triata C	VIII	
	- 04.54	50 11	* **		(K=II; K=190,C.)	In; R"=	H) (For	mula	100
		59.11	5.68		· •)				_50
					The procedure of Es	ample 1:	l b) is	used,	
	Fran	MPLE 13			substituting composing	(I) whit	come	harra d	
	Ethyl 4,6 - dihydroxy	u = 1234 -	tatenhad	4	(11) Inc resulting bro	oduct is	recruetal	lized	
50	isodumoline carb	ovulate (VII	T\ ∧o.•	<u></u>	from methyletnylketone	(Yield 1	1%).		105
	R'=C ₂ H ₅ ; R"=	H) (Formula	رن رير.	-ш,					
	ine procedure of	Frample 5	h) :	heer	A 1*				
	substituting compour	ad (I) with	compr	hara	Analysis				
	(AA), ICCI ystamzauon	from meths	inol oro	PS 2	Calculated for C15H21NO	λ. H₂O	(3/4)		
55	mst crop which is a	mixture of h	noth cie	and		C%	H%	N%	
	irans isomers, melting	at 180—190	°C (Yi	eld ·	Found	61.52	7.74	4.48	
	66,4%) and a second	crop meltir	g at 19	94—	A OWIN	CT 40			110
			J 4.			61.49	7.49	4.78	

	1,247	306	<u> </u>
_6			
	Example 17	Analysis	
	Market 4.6 - dibudrovy - 2 - ethyl - 1,2,3,4 -	Calculated for CnHiaNO, C% H% N%	55
		55.23 5.48 5.86	,,
	(XVII) (R=C ₂ H ₃ ; R'=CH ₃ ; R"=H)	33.03 5114	
5	(Farmula C)	Found 55.11 5.37 5.71	
_	The procedure of Example 4 b) is used,	33.11 3.37 5.11	
	- beginning the 40 g of compound (1) with	Example 20	
	40 g of compound (III) of Example 4. Field.	Toronto 2 3.4.5 - tetra-	60
	65%, m.p. 139—140°	hydro - 3 - (1H) - benzazepin - 2 - one	
10	Analysis	An agreeus solution of glyoxylic acid mono-	
	Calculated for C ₁₃ H ₁₇ NO,	budgets (6 g. 0.066 mole) in Water (10 iii) is	
	62.13 6.82 5.57	mound over 0.06 mole of noradrenami base.	65
	Found 62.13 6.91 5.67	an elightly: scratching the Walls of the con-	
15	02.13 0.72 515		
		magning which is suction filtered, wasned with	70
	Example 18	mater with alcohol and many with edici.	10
	Mixture of the mutual salts of cis and trans -	This is dried in air to constant weight to give	
	4 6 7 tribudrovy = 2 = methyl = 1,2,3,4 =	12 g (Yield: 80%) of product melting at	
	estrobudgo - isoquinoline 1 - Carooxylic	205°C, containing one mole of water.	
20	acide (XVIII) R=CHs; K=H; K =		
20	OLD and of 15.7.8 - tetrahydroxy - 3 -	Analysis	75
	-methyl - 2 3 4.5 - tetrahydro - 3 - (1/1)-	Calculated for C ₁₀ H ₁₁ NO ₅ . H ₂ O C% H% N%	
	benzazepin - 2 - one (XIX) (R=CH ₈ ;	49.38 5.39 5.76	
	formula D).	15,50	
25	An aqueous solution of glyoxylic acid mono-	Found 49.42 5.40 5.87	
	hydrate (0.03 mole) is poured over powdered		
	advenagin base (0.03 mole); the mixture is	Example 21	80
	thoroughly stirred and the whole solubilizes,	Transburdeners - 2 - isopropy -	
	after which the solution becomes discolored	2,3,4,5 - tetrahydro - 3 - (1H) - benza- zepin - 2 - one (XXI) (R=iso.C _s H ₇ ;	
30	and crystallizes spontaneously. The precipi-	zenin - 2 - one (XXI) (R=iso.C ₅ H ₇ ;	
	tate is suction filtered, washed with alcohol		
	and with ether, and is then dried in air to constant weight. Yield: 93%. m.p. 180°C with	An aqueous solution of glyoxylic acid mono-	85
	stant Weight. Held: 95 /6. In.p. 100	bydrate (1 g: 0.011 mole) is poured over 180-	
	decomposition.	meanalin base (7 g: () () 1 mole). The mixture	
		becomes discolored and warms up slightly;	
35	Analysis	scratching the walls with a rod gives a crystal-	90
33	Calculated for CuHuNO, . H ₂ O	line material which is suction filtered, washed	,,
	C% H% N%	with water, then with alcohol and finally with	
	51.36 5.87 5.44	ether, and is then dried in air to constant weight. Yield: 82%; m.p. 188—190°C.	
	Found 5.52 5.64	Weight. 11cld: 62 %, In.p. 100 270	
40	51.69 5.62 5.64	Analysis	
		Calculated for CaHaNO	95
	_ **	Analysis Calculated for C ₂ H ₁₇ NO ₃ C% H% N% O%	
	EXAMPLE 19	58.42 6.41 5.24 29.93	
	1,5,7,8 - Tetrahydroxy - 3 - methyl - 2,3,4,5 -	Found	
	tetrahydro - 3(1H) - benzazepin - 2 - one	58.53 6.53 30.03	
	(XIX) (R=SH ₃ ; formula D) 5 g of the product prepared in Example 18		
45	(mixture XVIII+XIX) are contacted in the	Results of toxicological and pharmacological	100
	cold with 10 ml of N HCl during 24 hours	test corried out with some of the products	
	after which an insoluble portion is found to	according to the invention, and particularly	
	The letter is suction filtered and then	those of the preceding examples (the releiched	
50	washed with alcohol and with ether. I his in-	mumbers of the products are given in said	
50	soluble fraction (1.3 g) constitutes the pure	examples) will now be given for illustrative	105
	product (XIX); m.p. 185—188°; Yield: 26%	purposes.	

	I, Acute toxicity LD ₅₀ in mice, mg/kg				
	Product No.	Route of administration:			
5	I I I I I I I I I I I I I I I I I I I	intra-venous	intra-peritoneal	per os	
	Îa	> 800	>1000	>1000	
		>1000	>1000	>1000	
	<u>Ib</u>	> 800	>1000	>1000	
	, II	-	> 600	>1000	
	III	> 800	>1000	>1000	
10	IV	250	. 500		
	VI	300		>1000	
	Mixture VIa+VIb	350	600	1000	
	VIII		600	1000	
	IX	160	450	800	
15 .	XI.	180	>1000	>1000	
		150	>1000	>1000	
	XIII	650	>1000	>1000	
	xv	420	. > 600	1000	
	Mixture XVIII+XIX		000	1000	
	(Ex. 18)	>1500	>1500		
20	XX `	> 500		>1500	
	Codein phosphate (for	- 300	>1000	>1000	
	comparative purposes)	65	120		

Thus, it is apparent that the acute toxicity of all products tested is extremely low and always much lower than of codein phosphate.

II. Systemic effects

At dosages of 2—20 mg/kg, by the intrevenous route in rat, guineapig or rabbit toonly effects found for some of the products
are a low and transient hypotension and a respiratory stimulation, also of short duration.
Only the two o-diphenoile materials tested
(mixture XVIII+XIX and compound XX)
induce a transient hypertension at strong dosdosges (dosage about 1000 to 2000 times that of
adrenalin and of nondertenalin to produce the

same effect). III. Anti-tussive activity

Products (I), (Ia) and (III) protect
markedly the quinea-pig against coughing induced by ammonia aerosols, according to the technique of C. A. Winter and L. Flataker (J. Pharmacol, exper. Therap., 1954, 112, 99).

Product (I) was compared with codein phosphate in decerebrated guinea-pig, coughing being induced by touching the inner tracheal walls with a small catheter, according to M. Lemeignan, G. Streichenberger & P.

Lechat (Thérapie, 21, 361)

50 In administration by the intra-perinosal rotue, 60 mg/kg of () and 10 mg/kg of coddein phosphate have a comparable activity, decreasing strongly the severity of the first of codein phosphate are inactive). It should be noted that (1) is free from any toxicity by the intra-perinosal rotue (LD₀, above 1 g/kg) whereas that of codein phosphate, by this route, is 310 mg/kg.

 Product (I) and its constituents (Ia) and (Ib), and also products (X), (XIII) and (XX) were submitted to R. Domenjoz's test (Arch. Exp. Pathol. Pharmacol., 1952, 215, 19) which comprises stimulating electrically the upper laryngeal nerve in cat while the trachae is connected through a canula with a Marey drum which records the respiration and its variations under the influence of coughing. Codein plosphate was used as reference material.

(I) and (Ib) have an anti-russive activity that is comparable in intensity to that of code-in phosphate at the same dosages. The activity of (Ia) is markedly lower. Duration of the action of (I) is comparable to that of codein phosphate and higher than that of (Ia) and

(Ib) administered separately.

The anti-tussive activity of (XIII) is close to that of (I) both with respect to intensity and to duration, that of (X) is close, as to intensity, but lower as to duration.

but lower as to duration, and that of (XX) is 80 marked, but lower than that of (I) with respect to intensity.

IV. Action on intestinal transit

Product (I) has no action on intestinal transit in mice, whereas codein phosphate slows it down strongly: after administration of a charcoal slurry to three lots of 10 mice, the average percentages of the length of intestine travelled by the charcoal are the following:

Reference animals: 59.7%
Treated with 75 mg/kg codein phosphate per os
Treated with 150 mg/kg of product (I) per os

60.7%

V. To conclude, the products according to the invention, and more particularly product (J), mutual salt of cis- and trans - 4,6 - di-hydroxy - 1,2,3,4 - tetrahydro - isoquinaldic acids, are endowed with anti-tussive properties equivalent to those of codein, with the follow-

ing advantages over the latter: acute toxicity practically nil, absence of paralysing action on the intestine and absence of respiratory depressant action.

They are applicable in human therapeutics for the treatment of coughing from any origin: tracheitis, rhinopharyngitis, laryngitis, bronchitis, acute and chronic pneumonopathy, influenza, spasmodic and reflex coughing, 10 coughing fits, whooping-cough, turberculosis.

Therefore, the present invention relates also to a therapeutic composition containing, as active principle, a reaction product as defined previously together with a pharmaceutically

15 acceptable vehicle.

The composition of the invention is administrable by the oral or rectal route, for example at a daily dosage regimen of 0.05-1 g, or more, of active principle, according to

20 the case. For administration, the composition is formulated in particular as tablets, coated tablets or capsules, containing for example 25-250 mg of active ingredient per unit dose, or as

25 sweetened and flavored granules or suspensions containing 0.5-5%, by weight, of active ingredient, or also in the form of suppositories containing each 50-500 mg of active ingre-

In such pharmaceutical forms, the active ingredient is associated with the suitable wellknown vehicles or excipients.

WHAT WE CLAIM IS:-1. A reaction product of one mole of an 35 arylethanolamine of formula

with one or more of a glycolic acid or ester thereof of formula

in which R and R', which may be the same or different, represent hydrogen or an alkyl group having from 1 to 8 carbon atoms and R" is hydrogen or a hydroxy group.

2. A compound of formula

in which R, R' and R" have the same meanings as in claim 1, or a compound of equi-molar quantities of the cis and trans forms of said compound (C) when R' is hydrogen.

3. A compound of formula

in which R has the same meaning as in claim

4. A mixture of a compound according to claim 2 and a compound according to claim

5. A compound of equimolar quantities of cis- and trans - 4,6 - dihydroxy - 2 - methyl -1,2,3,4 - tetrahydroisoquinoline 1 - carboxy-

lic acids. 6. A process for the production of a comcounds of formula (C), as hereinbefore defined, and/or a compound of equimolar quantities of the cis and trans forms of said compound (C), where R' is hydrogen, and/or of formula (D), as hereinbefore defined, which process comprises reacting an arylethanolamine of formula (A), as hereinbefore defined, with a glyoxylic acid or ester thereof of for-

mula (B), as hereinbefore defined. 7. A process according to claim 6, in which said glyoxylic acid or ester thereof is used in

aqueous or alcoholic solution. 8. A process according to claim 6, sub-(B) stantially as hereinbefore described with reference to any one of the foregoing

Examples.

9. A compound of formula (C) or a compound of equimolar quantities of the cis and trans forms of said compound (C) when produced by a process according to any one of claims 6 to 8.

10. A compound of formula (D) when pro-

duced by a process according to any one of in the form of a tablet, a coated tablet or a claims 6 to 8.

11. A therapeutic composition comprising a compound according to any of claims 2, 3, 9 or 10 and a pharmaceutically acceptable vehicle.

12. A composition according to claim 11, in unit dosage form.

13. A composition according to claim 12, 10 suitable for oral administration, in which each unit dose contains from 25 to 250 mg of said

15 15. A composition according to claim 12, in the form of a suppository containing 50 to 500 mg of said compound.

16. A composition according to claim 11,

in the form of sweetened and flavoured granules or suspension containing from 0.5 to 5 per cent by weight of said compound.

17. A therapeutic composition according to claim 11, substantially as hereinbefore des-

14. A composition according to claim 13, MARKS & CLERK.

Printed for Hajesty's Stationery Office, by the Courier Press, Learnington Spa, 1971.
Published by The Patent Office, 26 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.

ENGLISH ABSTRACT FOR SU1238732

100

```
1 / 1 WPAT - The Thomson Corp.
Derwent Accession :
  1983-56711K [24]
CPI Accession :
  C1983-055068
Title :
  Alpha-2 antagonist compsn. contg. 3-benzazepine cpd. esp. for reducing
  intra=ocular pressure and blood pressure
Derwent Class :
Patent Assignee :
  (SMIK) SMITHKLINE BECKMAN CORP
Inventor .
  DEMARINIS RM: HIEBLE JP: MATTHEWS WD
Nbr of Patents :
Nbr of Countries :
  27
Patent Number :
  EP--80779
                 A 19830608 DW1983-24 Eng 29p *
  AP: 1982EP-0201507 19821129
 JP58092616
                A 19830602 DW1983-28 Jpn
 AP: 1982JP-0201817 19821116
                 A 19820602 DW1983-29 Eng
 AP: 1982AU-0090172 19821104
  NO8203990
                A 19830620 DW1983-31 Nor
  AP: 1982NO-0003990 19821126
  FI8203715
                A 19830729 DW1983-36 Fin
  AP: 1982FI-0003715 19821101
                A 19830801 DW1983-37 Dan
  AP: 1982DK-0004931 19821105
  HUT027615
                 T 19831028 DW1983-49 Hun
                A 19831207 DW1984-02 Por
  PT--75838
  AP: 1982PT-0075838 19821112
  ZA8207887
                 A 19831018 DW1984-05 Enq
  AP: 1982ZA-0007887 19821028
  DD-205896
                A 19840111 DW1984-19 Ger
 AP: 1982DD-0245313 19821129
  US4465677
                 A 19840814 DW1984-35 Enq
  AP: 1982US-0398015 19820714
  CS8208075
                 A 19840717 DW1984-40 Cze
  ES8405769
                A 19841001 DW1984-49 Spa
 AP: 1982ES-0517697 19821126
                 A 19841030 DW1985-18 Rum
  AP: 1982RO-0109135 19821125
 EP--80779
                B 19860716 DW1986-29 Eng
 AP: 1982EP-0201507 19821129
```

```
DE3272044
                 G 19860821 DW1986-35 Ger
  CA1214165
                 A 19861118 DW1986-51 Enq
  AP: 1982CA-0414027 19821022
  SII1 238732
                 A 19860615 DW1987-05 Rus
 AP: 1982SU-3513948 19821125
  IL--67092
                 A 19870916 DW1987-47 Enq.
  AP: 1982IL-0067092 19821027
Priority Number :
  1982EP-0305361 19821008; 1981US-0325249 19811127; 1982US-0398015
                                                                          19820714
Intl Patent Class :
  C07D-223/16; A61K-031/33; A61K-031/55; A61P-025/02; A61P-027/02;
  A61P-027/06; A61P-009/12; C07D-233/00; C07D-233/16; C07D-223/00;
  A61K-000/00; A61P-025/00; A61P-027/00; A61P-009/00; C07C-000/00;
  C07D-000/00
Advanced IPC (V8) :
  C07D-223/16 [2006-01 A F I R - -]; A61K-031/33 [2006-01 A - I R - -];
  A61K-031/55 [2006-01 A L I R - -]; A61K-031/55 [2006-01 A - I R - -];
  A61P-025/02 [2006-01 A L I R - -]; A61P-027/02 [2006-01 A L I R - -];
  A61P-027/06 [2006-01 A L I R - -]; A61P-009/12 [2006-01 A L I R - -];
  C07D-223/16 [2006-01 A - I R - -]; C07D-233/00 [2006-01 A - I R - -];
  CO7D-233/16 [2006-01 A - I R - -]
Core IPC (V8) :
  C07D-223/00 [2006 C F I R - -]; A61K-000/00 [2006 S - I R - -];
  A61K-031/33 [2006 C - I R - -]; A61K-031/55 [2006 C L I R - -];
  A61K-031/55 [2006 C - I R - -]; A61P-025/00 [2006 C L I R - -];
  A61P-027/00 [2006 C L I R - -]; A61P-009/00 [2006 C L I R - -];
  C07C-000/00 [2006 S - I R - -]; C07D-000/00 [2006 S - I R - -];
  C07D-223/00 [2006 C - I R - -]: C07D-233/00 [2006 C - I R - -]
US Patent Class :
  514213000 540594000
Designated States :
  EP--80779
  Regional States: AT BE CH DE FR GB IT LI LU NL SE
  Regional States: AT BE CH DE FR GB IT LI LU NL SE
Abstract :
  EP--80779 A
  An alpha-2 antagonist compsn. comprises a carrier and a 3-benzazepine
  cpd. of formula (I) or its pharmaceutically acceptable acid addn. salt.
  (R is 1-3C alkyl or allyl. X is halo). Most pref. (I) is 6-chloro
  -2,3,4,5-tetrahydro-3-methyl-1H-benzazepine (Ia) used as its
  hydrochloride salt. Esp. (I) are used to reduce intraocular pressure
  (treatment of glaucoma); as cardiovascular agents (treatment of
  congestive heart failure, angina pectoris and thrombosis) and as
  antihypertensives. They have no direct effect on pupil size and no
  effect on heart rate or blood pressure in normotensive subjects.
Manual Codes :
  CPI: B06-D04 B12-E01 B12-F01 B12-F02 B12-F05 B12-H02 B12-L04
Update Basic :
  1983-24
Update Equiv. :
  1983-28; 1983-29; 1983-31; 1983-36; 1983-37; 1983-49; 1984-02; 1984-05;
  1984-19; 1984-35; 1984-40; 1984-49; 1985-18; 1986-29; 1986-35; 1986-51;
  1987-05; 1987-47
```